Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis)

Michael D. Miedema, MD, MPH; Zeina A. Dardari, MS; Sina Kianoush, MD, MPH; Salim S. Virani, MD, PhD; Joseph Yeboah, MD, MS; Thomas Knickelbine, MD; Veit Sandfort, MD; Carlos J. Rodriguez, MD, MPH; Khurram Nasir, MD, MPH; Michael J. Blaha, MD, MPH

Background—The potential impact of the 2016 United States Preventive Services Task Force (USPSTF) guidelines on statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) warrants further analysis.

Methods and Results—We studied participants from MESA (Multi-Ethnic Study of Atherosclerosis) aged 40 to 75 years and not on statins. We compared statin eligibility at baseline (2000–2002) and over follow-up between USPSTF and the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Coronary artery calcium (CAC) was measured at baseline. Absolute ASCVD event rates were calculated according to eligibility categories for each guideline. Among 4962 MESA participants (aged 59.3±8.8 years, 47.2% female), compared with ACC/AHA guidelines, baseline statin eligibility by USPSTF was significantly lower (34.4% versus 49.1%) and increased less over time (39.1% versus 59.1%) at examination 5 [years 2010–2012]. Compared with ACC/AHA, participants eligible by USPSTF were less likely to have zero CAC at baseline (36.6% versus 41.2%) and had higher rates of hard ASCVD events per 1000 person-years (11.6 [95% confidence interval, 10.2–13.3] versus 10.0 [8.9–11.3]). The hard ASCVD event rate in those eligible by ACC/AHA but not USPSTF was 6.5 (4.9–8.5) events per 1000 person-years, with the rate varying significantly according to baseline CAC (4.2 [2.7–6.7] events in those with CAC=0, 12.8 [8.3–19.9] events in those with CAC >100).

Conclusions—In MESA, compared with ACC/AHA, the USPSTF statin guidelines resulted in a 15% absolute decrease in eligibility. Participants with discordant eligibility had ASCVD rates that varied significantly according to baseline CAC, suggesting CAC could aid clinical decision making for statins in these individuals. (J Am Heart Assoc. 2018;7:e008920. DOI: 10.1161/JAHA.118.008920.)

Key Words: guideline • primary prevention • statin therapy

In 2016, the United States Preventive Services Task Force (USPSTF) released guidelines on statin use for the primary prevention of atherosclerotic cardiovascular disease (ASCVD).1 These guidelines recommended that individuals aged 40 to 75 years with 1 or more major ASCVD risk factors (hypertension, tobacco use, diabetes mellitus, or dyslipidemia) and a 10-year ASCVD risk ≥10% initiate statin therapy. Similar to the USPSTF guidelines, the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for the treatment of blood cholesterol recommended a risk-based approach to allocation of statin therapy in primary prevention,2 with an important focus on a clinician–patient risk discussion before initiation of statin therapy.3 The ACC/AHA guidelines identified a lower threshold for initiating statin therapy compared with the USPSTF guidelines, recommending statins for individuals with a 10-year ASCVD risk ≥7.5%.
Clinical Perspective

What Is New?

- Using data from MESA (Multi-Ethnic Study of Atherosclerosis), we found that application of the United States Preventive Services Task Force statin guidelines resulted in a 15% absolute decrease in statin eligibility compared with the 2013 American College of Cardiology/American Heart Association guidelines.
- MESA participants with discordant statin eligibility according to the 2 guidelines had atherosclerotic cardiovascular disease event rates that varied significantly according to baseline coronary artery calcium.

What Are the Clinical Implications?

- Healthcare providers and organizations should understand that adoption of the USPSTF guidelines, compared to the ACC/AHA guidelines, will lead to a significant decrease in statin eligibility at a population level.
- For individuals with discordant statin recommendations, coronary artery calcium testing may be useful as a tool to guide clinical decision making regarding statin use.

Importantly, the presence of 1 major ASCVD risk factor is not required by the ACC/AHA guidelines, leading to the observation that individuals may be eligible for statin therapy based on age alone. Prior studies have demonstrated that age plays a significant role in determining statin eligibility according to the ACC/AHA guidelines. The implications of not recommending statin therapy for this significant portion of the US population are unclear. The goal of this analysis was to compare the prevalence of statin eligibility according to the 2 guidelines in MESA (Multi-Ethnic Study of Atherosclerosis) participants at baseline and over 4 follow-up examinations as well as to analyze the prevalence of coronary artery calcium (CAC) at baseline according to guideline eligibility categories. Additionally, we sought to analyze ASCVD event rates over time according to statin eligibility categories within each guideline as well as in those individuals with discordant recommendations.

Methods

Study Design and Participants

MESA is a community-based prospective cohort study of asymptomatic individuals to determine factors associated with the prevalence, incidence, progression, and implications of subclinical and clinical ASCVD. Details of the MESA study design and objectives have been previously reported. Briefly, 6814 participants aged 45 to 84 years old who were free of clinical cardiovascular disease at baseline were enrolled between 2000 and 2002 (baseline visit) at 6 US field centers (Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles, CA; New York, NY; and St. Paul, MN). Four additional follow-up visits (examinations 2–5) were conducted in 2002 to 2004, 2004 to 2006, 2005 to 2007, and 2010 to 2012. This study was approved by the institutional review boards at each center and all participants provided written informed consent. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Use of statin therapy, including frequency and dosage, was evaluated by self-report and also review of pharmacy containers for all medications used during the 2 weeks preceding the MESA visit. Of the 6814 MESA participants at baseline, we excluded 806 participants aged >75 years old (both statin guidelines target individuals aged 40–75 years old), 859 on statin therapy at baseline, 3 participants missing statin use data, and 184 with a low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL (both guidelines exclude these individuals because of probable familial hypercholesterolemia), leaving 4962 individuals in the baseline analysis.

Measurement and Definition of CVD Risk Factors

Systolic and diastolic blood pressure were measured 3 times using an automated sphygmomanometer (Dinamap, Critikon, Tampa, FL), with 1-minute intervals, and the mean of the last 2 measurements was used. The Collaborative Studies Clinical Laboratory at Fairview-University Medical Center (Minneapolis, MN) measured concentrations of total and high-density lipoprotein cholesterol, triglycerides, and plasma glucose, after a 12-hour fast. LDL-C was calculated using the Friedewald equation.

Traditional ASCVD risk factors were identified based on definitions used by the USPSTF guidelines. Hypertension was defined as a systolic blood pressure ≥140 mm Hg, or a diastolic blood pressure ≥90 mm Hg, or antihypertensive medication use. Diabetes mellitus was defined as a fasting glucose of ≥7 mmol/L (126 mg/dL) or use of hypoglycemic medication (oral agents and/or insulin). Dyslipidemia was defined as an LDL-C >130 mg/dL or a high-density lipoprotein cholesterol <40 mg/dL. Tobacco use was defined as current tobacco within the last 30 days of the time of the baseline MESA examination.

Measurement of CAC

CAC is not included in the primary eligibility criteria for either guideline. However, MESA includes CAC scores on everyone,
enabling analysis of the burden of subclinical coronary atherosclerosis in different eligibility categories for each guideline. CAC scoring was performed with cardiac-gated chest computed tomography (CT) utilizing either an electron-beam CT scanner (Los Angeles, Baltimore, and New York) or a multidetector CT system (Chicago, St. Paul, and Forsyth County). All patients were scanned twice and CAC Agatston scores were averaged. A cardiologist or radiologist interpreted all scans at the MESA CT reading center (Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center).

Assessing Statin Eligibility Based on the USPSTF and the ACC/AHA Guidelines

As described in the guidelines for both the USPSTF and ACC/AHA, 10-year ASCVD risk was calculated by the Pooled Cohorts Equation (PCE), using data from the baseline MESA examination on age, sex, race, total cholesterol, high-density lipoprotein cholesterol, history of antihypertensive treatment, and diabetes mellitus. Participants were considered eligible according to the USPSTF guidelines if they had 1 or more major ASCVD risk factors (hypertension, tobacco use, diabetes mellitus, or dyslipidemia) and a 10-year ASCVD risk ≥10%. Participants with 1 major ASCVD risk factor and a 10-year risk of >7.5% and <10% were considered potentially eligible and participants with ASCVD risk of <7.5% were considered not eligible.

For primary prevention in individuals with an LDL-C <190 mg/dL, the ACC/AHA guidelines recommend moderate- to high-intensity statin therapy for patients with diabetes mellitus or individuals with an estimated 10-year ASCVD risk ≥7.5%. Per ACC/AHA guidelines, individuals with a 10-year ASCVD risk ≥5% and <7.5% were considered potentially eligible, and individuals with a 10-year ASCVD risk <5% were considered not eligible for statin treatment.

To assess eligibility over time, we reassessed eligibility at each MESA examination based on updated risk factor data and recalculating 10-year ASCVD risk. Individuals were excluded at each follow-up visit if they had developed ASCVD or started statin therapy. Of the 4962 individuals included in our study at baseline, 1062 were excluded at examination 2, 375 at examination 3, 455 at examination 4, and 1035 at examination 5, leaving 2035 participants who remained free of ASCVD and not on statin therapy at the time of examination 5.

Assessment of CVD Outcomes During Follow-Up

MESA staff contacted each participant or a family member about interim hospital admissions, outpatient diagnoses of ASCVD, and deaths at 9-to-12-month intervals. Follow-up telephone interviews were completed in 92% of living participants or relatives of deceased individuals. Medical records were successfully obtained for ≈98% of hospitalized events and 95% of outpatient cardiovascular diagnoses. Two physicians from the MESA mortality and morbidity review committee independently adjudicated events. In the event of a disagreement, a consensus was made by the full committee.

The PCE used for risk calculation in both guidelines calculates the 10-year risk for hard ASCVD outcomes including nonfatal myocardial infarction, coronary heart disease (CHD) death, and fatal or nonfatal stroke. We therefore used a similar definition for hard ASCVD events. Hard CHD included myocardial infarction, resuscitated cardiac arrest, and CHD death. Hard ASCVD included hard CHD events plus nonfatal and fatal stroke. All CHD included coronary revascularization in addition to hard CHD events. All ASCVD included all CHD plus stroke and transient ischemic attacks. A more detailed description of the follow-up methods and event classification is available on the MESA website.

Statistical Analysis

We tabulated baseline characteristics for the total population, across statin-eligibility categories as defined by the USPSTF and ACC/AHA guidelines, and the “discordant” group that was statin eligible by ACC/AHA but not USPSTF criteria. Continuous variables were presented as mean±SD for normally distributed data and medians with interquartile ranges for non–normally distributed data. Categorical data were presented as frequencies and proportions. We calculated changes in statin eligibility over time, determining changes in the absolute prevalence of statin eligibility for each guideline at subsequent MESA follow-up visits as well as relative percentage increases in eligibility compared with baseline.

Absolute ASCVD event rates were calculated by dividing the total number of events by total person-years contributed (expressed per 1000 person-years) based on statin eligibility categories at the time of the baseline examination. Events were also presented as total number and proportion of each statin-eligibility category. Kaplan–Meier survival curves were constructed for ASCVD events in each statin-eligibility guideline definition. The log-rank was used to test the equality of survivor functions among statin-eligibility groups.

Using eligibility categories at the time of the baseline examination, Cox proportional hazards regression models were used to model time-to-first event for each ASCVD outcome including hard ASCVD, all ASCVD, hard CHD, all CHD, myocardial infarction, and stroke. Using not statin eligible as the reference group in both guideline definitions, comparisons of event risk were made between the eligibility categories. To control for potential confounding, income, MESA site, and body mass index were included in our adjusted models. All statistical analyses were conducted.
using STATA 13 (Stata Corp., College Station, TX). A P value of <0.05 was considered statistically significant.

Results
The baseline characteristics of the 4962 MESA participants (mean age 59.3±8.8 years, 47.2% female) included in the study are shown in Table 1, stratified according to statin eligibility by the USPSTF and ACC/AHA guidelines. According to the USPSTF guidelines, 1709 (34.4%) of MESA participants at the time of the baseline examination were eligible for statin therapy, 384 (7.7%) were potentially eligible, and 2869 individuals (57.8%) were not eligible. According to ACC/AHA guidelines, 2436 (49.1%) of MESA participants were statin eligible, 617 (12.4%) were potentially statin eligible, and 1909 individuals (38.5%) were not eligible according to ACC/AHA.

The baseline prevalence of CAC and higher ASCVD event rates that varied significantly according to baseline CAC, as those with CAC zero had a hard ASCVD rate of 4.2 (95% CI, 2.7–6.7) per 1000 patient-years compared with a rate of 12.8 (95% CI, 8.3–19.9) in those with CAC >100.

Discussion
In MESA, we found that statin eligibility according to the 2016 USPSTF guidelines was significantly lower compared with the 2013 ACC/AHA guidelines, with 34% of MESA participants eligible according to USPSTF guidelines compared with 49% eligible for a risk-based statin discussion according to the ACC/AHA guidelines. Statin eligibility in the MESA cohort increased over time by both guidelines, though the increase was larger for the ACC/AHA guidelines. As would be expected because of a higher risk threshold for eligibility, compared with ACC/AHA, participants eligible by USPSTF had a higher baseline prevalence of CAC and higher ASCVD event rates over time. Importantly, the 15% of MESA participants eligible by ACC/AHA but not USPSTF had modestly elevated ASCVD event rates that varied significantly according to baseline CAC, suggesting CAC could aid clinical decision making for statin therapy in individuals with discordant eligibility.

Applying the USPSTF Guidelines: Implications for the US Population
The recent NHANES data comparing eligibility between USPSTF and ACC/AHA guidelines estimated that 36.3% of the US adult population aged 40 to 75 years without known ASCVD is either already on a statin or eligible for statin therapy according to the
Table 1. Baseline Characteristics of 4692 MESA Participants Based on Statin Eligibility According to the USPSTF and the 2013 ACC/AHA Guidelines

| Participants’ Characteristics | Total (N=4692)* | Statin Eligible | Potentially Statin Eligible | Not Statin Eligible | Discordant Recommendations for Statin Eligibility† (N=727) |
|------------------------------|-----------------|----------------|---------------------------|-------------------|----------------------------------------------------------|
| Age, y                       | 59.3±8.8        | 66.1±6.6       | 64.9±7.2                  | 59.5±6.3          | 58.4±5.7                                                 | 55.3±7.6                                                 | 52.5±5.7                                                 | 62.1±7.9                                                 |
| Female (%)                   | 2622 (47.16)    | 616 (36.0)     | 943 (38.7)                | 185 (48.8)        | 301 (48.8)                                               | 1821 (63.5)                                              | 1378 (72.2)                                              | 327 (45.0)                                               |
| Race                         |                 |                |                           |                   |                                                        |                                                         |                                                         |                                                         |
| White                        | 1862 (37.5)     | 545 (31.9)     | 811 (33.3)                | 119 (31.0)        | 374 (60.9)                                               | 1311 (44.9)                                              | 817 (42.8)                                              | 266 (36.6)                                               |
| Black                        | 1381 (27.8)     | 625 (36.6)     | 825 (33.9)                | 135 (35.2)        | 231 (37.2)                                               | 1198 (41.8)                                              | 366 (19.2)                                              | 200 (27.5)                                               |
| Hispanic                     | 1120 (22.6)     | 365 (21.4)     | 539 (22.1)                | 98 (25.5)         | 124 (20.3)                                               | 657 (22.9)                                               | 456 (23.9)                                              | 174 (23.9)                                               |
| Chinese American             | 599 (12.07)     | 174 (10.2)     | 261 (10.7)                | 32 (8.3)          | 68 (11.0)                                                | 393 (13.7)                                               | 270 (14.1)                                              | 87 (12.0)                                                |
| Education (above high school)| 3251 (65.8)     | 983 (57.5)     | 1461 (60.1)               | 240 (62.5)        | 409 (66.3)                                               | 2028 (71.2)                                              | 1381 (73.0)                                             | 478 (66.0)                                               |
| Income ($≥40 000)            | 2520 (52.7)     | 667 (41.2)     | 1021 (44.1)               | 186 (50.1)        | 363 (59.9)                                               | 1667 (59.7)                                              | 1136 (61.1)                                             | 354 (50.6)                                               |
| Current smoking              | 728 (14.7)      | 371 (21.7)     | 456 (18.7)                | 83 (21.6)         | 105 (17.0)                                               | 274 (9.6)                                                | 167 (8.8)                                               | 85 (11.7)                                                |
| BMI, kg/m²                   | 28.4±5.6        | 28.9±5.3       | 28.8±5.4                  | 29.0±5.3          | 28.5±5.4                                                 | 27.9±5.8                                                 | 27.8±5.9                                                | 28.4±5.6                                                 |
| LDL-C, mg/dL                 | 118.2±28.8      | 121.3±29.7     | 119.7±29.2                | 124.4±29.7        | 122.3±28.9                                               | 115.5±27.8                                               | 115.0±28.0                                              | 115±27.6                                                 |
| HDL-C, mg/dL                 | 51.0±15.0       | 47.1±14.0      | 48.5±14.3                 | 48.7±13.2         | 49.9±14.1                                               | 53.6±15.3                                                | 54.7±15.4                                               | 51.2±14.5                                                 |
| Total cholesterol, mg/dL     | 194.3±32.1      | 191.6±32.9     | 194.8±32.5                | 199.4±34.2        | 197.7±32.6                                               | 192.5±31.2                                               | 192.5±31.3                                              | 191.7±31.5                                               |
| Hypertension                 | 1927 (38.8)     | 1195 (69.9)    | 1420 (58.3)               | 201 (52.3)        | 191 (31.0)                                               | 531 (18.5)                                               | 316 (16.6)                                              | 225 (31.0)                                               |
| Diabetes mellitus            | 509 (10.3)      | 398 (23.3)     | 509 (20.9)                | 34 (8.9)          | 0 (0)                                                    | 77 (2.7)                                                  | 0 (0)                                                    | 111 (15.3)                                               |
| Anti-hypertensive medications| 1537 (31.0)     | 913 (53.4)     | 1119 (45.9)               | 147 (38.3)        | 147 (23.8)                                               | 477 (16.6)                                               | 271 (14.2)                                              | 206 (28.3)                                               |
| Nonstatin lipid-lowering medications | 68 (1.4) | 37 (2.2) | 48 (2.0) | 6 (1.6) | 6 (1.0) | 25 (0.9) | 14 (0.7) | 11 (1.5) |
| Family history of heart attack | 1908 (40.8) | 692 (43.8) | 971 (42.8) | 165 (45.0) | 245 (42.5) | 1051 (38.6) | 692 (37.8) | 279 (40.6) |
| ASCVD risk, %                | 10.1±9.8        | 20.3±9.5       | 17.1±9.6                  | 8.7±7.1           | 6.2±7.2                                                  | 4.2±3.6                                                   | 2.4±1.4                                                  | 9.6±3.8                                                  |
| ≥2 risk factors†             | 1563 (31.6)     | 1033 (60.4)    | 1244 (51.1)               | 161 (41.9)        | 153 (24.8)                                               | 369 (13.0)                                               | 168 (8.8)                                                | 211 (29.1)                                               |
| No risk factors†             | 1266 (25.6)     | 0 (0)          | 266 (10.9)                | 0 (0)             | 144 (23.3)                                               | 1266 (44.5)                                              | 856 (45.3)                                               | 266 (36.7)                                               |
| CAC = 0                      | 2869 (57.8)     | 625 (36.6)     | 1004 (41.2)               | 219 (57.0)        | 350 (56.7)                                               | 2025 (70.6)                                              | 1515 (79.4)                                             | 379 (52.1)                                               |
| CAC > 100                    | 858 (17.3)      | 560 (32.8)     | 705 (28.9)                | 66 (17.2)         | 73 (11.8)                                                | 232 (8.1)                                                | 80 (4.2)                                                 | 145 (19.9)                                               |
| CAC > 400                    | 326 (6.6)       | 246 (14.4)     | 293 (12.0)                | 23 (6.0)          | 22 (3.6)                                                 | 57 (2.0)                                                 | 11 (0.6)                                                 | 47 (6.5)                                                 |

ACC/AHA, American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CAC, coronary artery calcium; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MESA, Multi-Ethnic Study of Atherosclerosis; USPSTF, US Preventive Services Task Force.

*Participants who were taking statin, were younger than 40 or older than 75 years old, or had LDL-C >190 were excluded. Numbers may not add up to total or 100% because of missing values or rounding, respectively.

†Considered as participants who were statin-eligible according to the 2013 ACC/AHA guidelines but potentially eligible (n=384) or not eligible (n=343) according to USPSTF guidelines.

‡Major risk factors included dyslipidemia (HDL-C <40 or LDL-C >130), hypertension (systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg or use of antihypertensive medications), diabetes mellitus (fasting plasma glucose ≥126 mg/dL or use of hypoglycemic medications), and current smoking status.
Figure. A, Statin eligibility according to USPSTF and ACC/AHA guidelines in 4962 MESA participants at baseline (2000–2002) and in those who remained free of ASCVD and off of statin therapy during follow-up (through 2012). B, The prevalence of CAC=0 and CAC≥100 across statin eligibility categories according to USPSTF and ACC/AHA guidelines in 4962 MESA participants at baseline. C, Absolute cardiovascular event rates per 1000 patient-years in MESA participants eligible for statin therapy according to USPSTF and ACC/AHA guidelines as well as the discordant group who were eligible by ACC/AHA but not USPSTF guidelines. ACC/AHA indicates American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CHD, coronary heart disease; CVD, cardiovascular disease; MESA, Multi-Ethnic Study of Atherosclerosis; MI, myocardial infarction; USPSTF, United States Preventive Services Task Force.
Table 2. Absolute Cardiovascular Event Rates Per 1000 Person-Years With 95% CIs by Statin Eligibility According to the USPSTF and the 2013 ACC Guidelines Over 12-Year Follow-Up of 4962 MESA Participants

| ASCVD Events | Total (%) | Statin Eligible | Potentially Statin Eligible | Not Statin Eligible |
|--------------|-----------|-----------------|----------------------------|---------------------|
|              |           | USPSTF (N=1709) | ACC/AHA (N=2436) | USPSTF (N=384) | ACC/AHA (N=617) | USPSTF (N=1048) | ACC/AHA (N=1909) |
| Hard ASCVD   | 326 (6.6) | 11.6 (10.2–13.3) | 10.0 (8.9–11.3) | 6.1 (4.1–8.9) | 4.1 (2.8–5.9) | 2.8 (2.3–3.5) | 1.8 (1.3–2.4) |
| All ASCVD    | 451 (9.0) | 16.5 (14.7–18.6) | 14.4 (13.0–16.0) | 10.3 (7.6–13.9) | 5.2 (3.8–7.2) | 3.7 (3.1–4.5) | 2.4 (1.8–3.1) |
| Hard CHD     | 200 (4.0) | 7.2 (6.1–8.6) | 6.0 (5.1–7.0) | 3.5 (2.1–5.8) | 2.4 (1.5–3.8) | 1.6 (1.3–2.1) | 1.2 (0.8–1.7) |
| All CHD      | 304 (6.1) | 10.8 (9.4–12.5) | 9.4 (8.3–10.6) | 7.6 (5.4–10.7) | 3.5 (2.4–5.2) | 2.5 (2.0–3.1) | 1.8 (1.3–2.4) |
| Total MI     | 150 (3.0) | 5.3 (4.4–6.5) | 4.4 (3.6–5.2) | 2.8 (1.6–4.9) | 2.0 (1.2–3.3) | 1.3 (0.9–1.7) | 1.0 (0.6–1.5) |
| Total stroke | 138 (2.7) | 4.7 (3.8–5.8) | 4.3 (3.6–5.2) | 2.6 (1.4–4.6) | 1.7 (0.9–2.9) | 1.3 (1.0–1.7) | 0.6 (0.4–1.0) |

USPSTF guidelines, compared with 45.8% already on a statin or eligible according to the ACC/AHA guidelines. This 9.5% absolute increase in statin eligibility for primary prevention equals to an estimated 9 million US adults.

We excluded individuals on statin therapy at baseline but found similar rates of eligibility according to the 2 guidelines (34% and 49%). Our data suggest that the discordance between the 2 guidelines may be higher in older, healthier populations because in MESA we found a 15% absolute increase in statin eligibility according to ACC/AHA compared with USPSTF. This higher prevalence of discordance is likely secondary to the older age of the MESA cohort (mean age 59 years) compared with the NHANES analysis (mean age 53 years), thus increasing the prevalence of those with elevated ASCVD risk regardless of the presence of other major risk factors. More than 10% of MESA participants eligible for statin therapy according to ACC/AHA were eligible despite having no major modifiable ASCVD risk factors. Additionally, the discordance between the 2 guidelines increased during follow-up, with only ≈25% of participants not statin eligible according to ACC/AHA guidelines at MESA examination 5 compared with ≈50% not eligible according to USPSTF.

What Is the Ideal Risk Threshold: 7.5% Versus 10%?

Although the 2.5% difference in the risk thresholds between the 2 guidelines may appear small, our data, in addition to the prior NHANES data, demonstrate that even small differences in risk thresholds can have substantial implications at a population level. The USPSTF performed a systematic review and produced an evidence report that was used to determine the 10% risk threshold. The authors of the USPSTF guidelines did cite data raising concern that the PCE may overestimate risk in modern populations as one of the rationales for choosing the more conservative 10% risk threshold. The USPSTF decided to require the presence of 1 major risk factor in addition to the 10% risk threshold because no randomized controlled trial has included patients without any major ASCVD risk factors.

Table 3. Absolute Cardiovascular Event Rates Per 1000 Person-Years With 95% CIs Over 12 Years of Follow-Up According to Baseline CAC in 727 MESA Participants Eligible for Statin Therapy by ACC/AHA Guidelines But Not Eligible by USPSTF

| Cardiovascular Events | All (N=727)* | CAC 0 (N=379) | CAC 1 to 100 (N=203) | CAC >100 (N=145) |
|-----------------------|-------------|---------------|----------------------|------------------|
| All ASCVD             | N. %        | 77 (10.6%)    | 24 (6.3%)            | 25 (12.3%)       | 28 (19.2%)       |
| Event rate            | 9.8 (7.8, 12.2) | 5.7 (3.8, 8.5) | 11.7 (7.9, 17.3)    | 18.5 (12.8, 26.8) |
| Hard ASCVD            | N. %        | 52 (7.2%)     | 18 (4.8%)            | 14 (6.9%)        | 20 (13.8%)       |
| Event rate            | 6.5 (5.0, 8.5) | 4.2 (2.7, 6.7) | 6.4 (3.8, 10.8)     | 12.8 (8.3, 19.9) |
| All CHD               | N. %        | 49 (6.7%)     | 10 (2.6%)            | 18 (8.9%)        | 21 (14.5%)       |
| Event rate            | 6.2 (4.7, 20.9) | 2.3 (1.3, 4.4) | 8.4 (5.3, 13.3)     | 13.6 (8.9, 20.9) |
| Hard CHD              | N. %        | 26 (3.6%)     | 6 (1.6%)             | 8 (3.9%)         | 12 (8.3%)        |
| Event rate            | 3.2 (2.2, 4.7) | 1.4 (0.63, 3.1)| 3.6 (1.8, 7.2)      | 7.5 (4.3, 13.2)  |

ACC/AHA indicates American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CHD, coronary heart disease; CIs, confidence intervals; MESA, Multi-Ethnic Study of Atherosclerosis; USPSTF, US Preventive Services Task Force.

*Includes participants who were statin eligible according to the 2013 ACC/AHA guidelines but potentially eligible (n=384) or not eligible (n=343) according to USPSTF guidelines.
A recent analysis from the Jackson Heart Study demonstrated that application of USPSTF to a cohort of blacks resulted in eligibility for 55% of individuals with CAC >0 compared with 69% eligibility in those with CAC >0 according to ACC/AHA guidelines. However, the study also found that blacks with discordant eligibility appeared to be at relatively low risk, with 4.1 ASCVD events per 1000 patient-years. In our multiethnic analysis, we found that individuals with discordant eligibility appeared to be at intermediate risk, because 20% had CAC scores >100 and they experienced 6.5 ASCVD events per 1000 person-years. More than 50% of the discordant group had a CAC score of zero and event rates varied significantly according to baseline CAC. Prior research has hypothesized that CAC could be utilized to more effectively allocate statin therapy to individuals most likely to benefit. The arbitrary nature of risk thresholds and the lack of definitive trial data for the utility of CAC as well as in individuals at elevated ASCVD risk because of age alone highlight the importance of the clinician–patient risk discussion in making the decision to start statin therapy.

Statins Allocation: The Importance of Absolute Risk

We found that ASCVD event rates during follow-up in MESA varied significantly according to eligibility categories by both guidelines, with individuals who were statin eligible having an ≈5-fold increase in ASCVD events compared with those who were not statin eligible. Both USPSTF and ACC/AHA rely largely on absolute risk to determine statin eligibility, a significant paradigm shift from prior Adult Treatment Panel guidelines (ATP III), which relied more heavily on LDL-C levels to determine statin eligibility.

The transition to utilizing absolute risk to determine statin allocation is evidence based because absolute risk has been shown to be a much stronger predictor of ASCVD events compared with LDL-C levels, and the cardiovascular benefit of statin therapy in randomized controlled trials has largely been independent of baseline LDL-C. A recent study from a large Midwestern cohort of patients who experienced ST-segment–elevation myocardial infarction demonstrated further evidence supporting a risk-based approach to statin allocation as application of the ACC/AHA guidelines, compared with ATP III guidelines, doubled the prevalence of pre-ST-segment–elevation myocardial infarction statin eligibility, with 39% of the cohort statin eligible before ST-segment–elevation myocardial infarction by ATP III compared with 79% being statin eligible with application of ACC/AHA guidelines.

Potential Opportunities for Improvement

The USPSTF and ACC/AHA guidelines both represent significant progress towards the optimal population-level allocation of statin therapy. However, these guidelines do have potential limitations. The PCE was modeled using data from an era when the prevalence of ASCVD risk factors and subsequent ASCVD event rates were significantly higher compared with more recent data. New risk equations based on more modern data may allow for more accurate risk assessment. Further risk assessment with CAC testing may provide a more robust method of individualized risk assessment, and CAC scoring has been hypothesized to more accurately identify individuals who are likely to benefit from statin therapy.

Strengths and Limitations

Our analysis has several strengths and limitations. Strengths include a large, multiethnic, geographically diverse, community-representative, sex-balanced cohort with data on baseline ASCVD risk factors and CAC, as well as long-term follow-up with thoroughly adjudicated ASCVD events. Long-term follow-up with good participant retention allowed for assessment of statin eligibility over 10 years of follow-up. Survivor bias and loss to follow-up may have influenced the prevalence of statin eligibility in the MESA cohort over time. As discussed above, the PCE calculator used to determine 10-year ASCVD risk has been shown to overestimate risk when applied to modern cohorts. However, how to best calibrate the PCE to modern populations is still subject to debate and the overestimation of risk was cited by the USPSTF as one of the reasons for choosing a more conservative risk threshold for consideration of statin therapy.

Conclusion

In conclusion, using data from MESA, we found that application of the USPSTF statin guidelines led to a 15% absolute decrease in statin eligibility compared with application of the 2013 ACC/AHA guidelines. Compared with ACC/AHA-eligible participants, those eligible by USPSTF had a higher prevalence of CAC and higher ASCVD event rates during follow-up, while those eligible by ACC/AHA but not USPSTF had a modestly elevated ASCVD event rate that varied significantly by baseline CAC. Healthcare providers and organizations should understand that the choice of which guideline to adopt and if and how to integrate CAC scoring may have a substantial impact on statin utilization and subsequent ASCVD outcomes at a population level.

Acknowledgments

The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions.
full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org.

Sources of Funding
This research was supported by grants (N01-HC-95159 to N01-HC-95166 and N01-HC-95169) from the National Heart, Lung, and Blood Institute.

Disclosures
None.

References

1. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FA, Gillman MW, Kemper AR, Krist AH, Kurth AE, Landefeld CS, LeFevre ML, Mangione CM, Phillips WR, Owens DK, Phipps MG, Pignone MP. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316:1997–2007.

2. Stone NJ, Robinson J, Lichtenstein AH, Merz N, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith SC, Levy D, Watson K, Wilson PF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129:2889–2934.

3. Martin SS, Sperling LS, Blaha MJ, Wilson PW, Gluckman TJ, Blumenthal RS, Stone NJ. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol. 2015;66:1361–1368.

4. Blaha MJ, Blumenthal RS. Risk factors: new risk-assessment guidelines more or less personalized? Nat Rev Cardiol. 2014;11:136–137.

5. Pencina MJ, D’Agostino RB Sr, Williams D, Peterson ED. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1929–1935.

6. Miedema MD, Lopez FL, Blaha MJ, Virani SS, Coresh J, Ballantyne CM, Folsom AR. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med. 2015;175:138–140.

7. Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ. Comparison of recommended eligibility for primary prevention statin therapy based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. JAMA. 2017;317:1563–1567.

8. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O’Leary D, Saad MF, Shea S, SzkoŁa M, Tracy RP. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871–881.

9. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measure- ment with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2005;234:35–43.

10. MESA Coordinating Center. MESA website. 2017. Available at: http://www.mesa-nhlbi.org. Accessed February 23, 2017.

11. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:2008–2024.

12. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382:1762–1765.

13. DeFilippis AR, Young R, McEvoy JW, Michos ED, Sandford V, Kronmal RA, McClelland RL, Blaha MJ. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38:598–608.

14. Shah RV, Spahilari A, Mwasongwe S, Carr JJ, Terry JG, Mentz RJ, Addison D, Hoffmann U, Reis J, Freedman JE, Lima JA, Corea A, Murthy VL. Subclinical atherosclerosis, statin eligibility, and outcomes in African American individ- uals: the Jackson Heart Study. JAMA Cardiol. 2017;2:644–652.

15. Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatston AS, Rivera JJ, Miedema MD, Sibley CT, Shaw LJ, Blumenthal RS, Budoff MJ, Krumholz HM. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology-American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atheroscle- rosis). J Am Coll Cardiol. 2015;66:1657–1668.

16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–3221.

17. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up study cohort. Lancet. 2008;371:923–931.

18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PG, McKillop JJ, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:3130–3137.

19. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357.

20. Sever PS, Dahlof B, Poulter NR, Wedel H, Beavers G, Caufield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nielsen M, O’Brien E, Ostergren J; ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial. Prevention of coronary artery and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361:1149–1158.

21. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koengen W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

22. Miedema MD, Garberich RF, Schnaidt LJ, Peterson E, Strauss C, Sharkey S, Knickelbine T, Newell MC, Henry TD. Statin eligibility and outpatient care prior to ST-elevation myocardial infarction. J Am Heart Assoc. 2017;6:e005333. DOI: 10.1161/JAHA.116.005333.

23. Benjamin EJ, Blaha MJ, Chiuee SE, Cushman M, Das SR, Deo R, de Ferranti S, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judde S, Lackland D, Lichtman JH, LisaBeth L, Liu S, Longenecker CT, Mackey RH, Magid DS, Mazzaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thigajaran RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–e603.

24. Yehboah J, Young R, McClelland RL, Delaney JC, Polonsky TS, Dawood FZ, Blaha MJ, Miedema MD, Sibley CT, Carr JJ, Burke GL, Goff DC Jr, Psaty BM, Greenland P, McClelland RM. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67:139–147.

25. Blaha MJ, Caiagos-Achirica M, Greenland P, McEvoy JW, Blankstein R, Budoff MJ, Dardari Z, Sibley CT, Burke GL, Kronmal RA, SzkoŁa M, Blumenthal RS, Nasir K. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133:849–858.